Subscribe to Newsletter
Business & Profession Professional Development, Other, Business and Innovation

R Is for Retina and Rejuvenation

sponsored by Ellex

Image courtesy of Erica Fletcher, MD, PhD

AMD affects 11 million people in the United States alone. As patient populations age, the number will surely grow – and so too will the need for effective treatment. Current therapies are almost entirely focused on tackling late-stage AMD; attempting to manage patient symptoms only after vision loss and/or serious damage have occurred. But what if there was a way to intervene earlier? That was the question Ellex asked itself  and then answered with 2RT® Retinal Rejuvenation Therapy – a new laser treatment that offers ophthalmologists the chance to delay the degeneration process in a significant proportion of patients with intermediate AMD – as highlighted in the LEAD trial (1).

So how does it work? 2RT uses Nanopix Technology™ – a nanosecond laser pulse in a unique pixelated beam profile – to exclusively target selected individual cells within compromised retinal pigment epithelium. This patented process stimulates a natural biological healing process in the retina – the rejuvenation – and improves the hydraulic conductivity of Bruch’s Membrane. And because the process is gentle, it does so without collateral damage to the overlying photoreceptor rods and cones of the retina.

In the extensive, multi-center LEAD clinical trial over 36 months, it was shown that 2RT achieves a significant reduction in the rate of progression to late-stage AMD in just over three quarters of intermediate AMD patients. Specifically, post-hoc analysis of the randomized, sham-controlled study of 292 patients showed that 2RT resulted in a clinically meaningful 77 percent reduction in the rate of disease progression in patients without co-existent reticular pseudodrusen (76 percent of patients enrolled). 

2RT Retinal Rejuvenation Therapy has already been approved for indications of clinically significant macular edema (CSME) in Europe and the United States – and for early AMD in Europe. And with its revolutionary approach to cell renewal, Ellex’s unique treatment program looks set to change the way ophthalmologists treat AMD the world over.

2RT® is not approved for sale in the USA for the indication of early AMD.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. RH Guymer et al., “Sub-threshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial”, Ophthalmology, (2018). PMID: 30244144
Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: